company background image
ACMELAB logo

ACME Laboratories DSE:ACMELAB Stock Report

Last Price

৳65.50

Market Cap

৳13.9b

7D

3.0%

1Y

-23.2%

Updated

22 Jun, 2024

Data

Company Financials

The ACME Laboratories Ltd.

DSE:ACMELAB Stock Report

Market Cap: ৳13.9b

ACMELAB Stock Overview

Manufactures, markets, and distributes generic pharmaceuticals formulation products in Bangladesh.

ACMELAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health2/6
Dividends3/6

The ACME Laboratories Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ACME Laboratories
Historical stock prices
Current Share Price৳65.50
52 Week High৳86.70
52 Week Low৳62.60
Beta0.061
11 Month Change-1.65%
3 Month Change-11.73%
1 Year Change-23.21%
33 Year Change-11.01%
5 Year Change-10.88%
Change since IPO-41.31%

Recent News & Updates

Recent updates

Shareholder Returns

ACMELABBD PharmaceuticalsBD Market
7D3.0%4.2%3.2%
1Y-23.2%-20.8%-24.3%

Return vs Industry: ACMELAB underperformed the BD Pharmaceuticals industry which returned -20.8% over the past year.

Return vs Market: ACMELAB exceeded the BD Market which returned -24.3% over the past year.

Price Volatility

Is ACMELAB's price volatile compared to industry and market?
ACMELAB volatility
ACMELAB Average Weekly Movement2.8%
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement5.4%
10% most volatile stocks in BD Market7.6%
10% least volatile stocks in BD Market3.4%

Stable Share Price: ACMELAB has not had significant price volatility in the past 3 months.

Volatility Over Time: ACMELAB's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19548,816Mizanur Sinhawww.acmeglobal.com

The ACME Laboratories Ltd. manufactures, markets, and distributes generic pharmaceuticals formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care, gastrointestinal, gynaecological, hand sanitizers, hormones and steroid, infusion products, musculoskeletal, nasal preparation, respiratory, sex stimulants, skin care, urogenital, and vitamins and minerals. It also provides ayurvedic, and herbal and nutraceutical products.

The ACME Laboratories Ltd. Fundamentals Summary

How do ACME Laboratories's earnings and revenue compare to its market cap?
ACMELAB fundamental statistics
Market cap৳13.86b
Earnings (TTM)৳2.42b
Revenue (TTM)৳30.81b

5.7x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACMELAB income statement (TTM)
Revenue৳30.81b
Cost of Revenue৳18.11b
Gross Profit৳12.71b
Other Expenses৳10.29b
Earnings৳2.42b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)11.44
Gross Margin41.24%
Net Profit Margin7.86%
Debt/Equity Ratio93.6%

How did ACMELAB perform over the long term?

See historical performance and comparison

Dividends

5.0%

Current Dividend Yield

29%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.